

Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

Product

Fund Name: **Biotechnology Fund**

Share Class Name: **Class I EUR Distribution Shares (IE00B3WVRB16)**

Manufacturer Name: **FundRock Management Company (Ireland) Limited (the "Manager") is the PRIIP manufacturer. Polar Capital LLP (the "Investment Manager") is the product manufacturer.**

Contact details: Website: www.polarcapital.co.uk and <https://bridgelfundservices.com/funds> Email: investor-relations@polarcapital.co.uk or call +44 (0) 20 7227 2700 or +353 (0) 1 566 9800 for more information.

Competent authority: The Central Bank of Ireland is responsible for supervising the Manager in relation to this Key Information Document. This PRIIP is authorised in Ireland. The Manager is authorised in Ireland and regulated by the Central Bank of Ireland. The Investment Manager is authorised in the UK and regulated by the Financial Conduct Authority.

This document was produced on 31 July 2025.

What is this product?**Type**

The Biotechnology Fund (the "Fund") is an investment fund. The Fund is a sub-fund of Polar Capital Funds plc, an umbrella type open-ended investment company with variable capital and segregated liability between funds, incorporated with limited liability under the laws of Ireland. This is an Undertaking for the Collective Investment in Transferable Securities (UCITS) product.

Term

This product does not have a maturity date.

Objectives

The objective of the Fund is to preserve capital and achieve long term capital appreciation by investing worldwide in the shares of biotechnology, diagnostics and life sciences tools companies.

Investment Policy

The Fund is broadly diversified across countries, biotechnology sectors and by market-cap (a measure of company size). The Fund may invest in financial derivatives (complex instruments based upon the value of underlying assets) for hedging, to reduce risk, to manage the Fund more efficiently, or to gain exposure to securities in a more efficient way. The Fund is actively managed and uses the NASDAQ Biotechnology Net Total Return Index (EUR) benchmark as a performance target and to calculate the performance fee. The currency of the Fund is USD and the currency of this share class is Euro (EUR).

Any income which the Fund generates may be paid out in the form of an annual dividend at the sole discretion of the Directors.

Sustainable Finance Disclosure Regulation

This Fund promotes environmental and/or social characteristics and is classified as an Article 8 fund under the EU's Sustainable Finance Disclosure Regulation. For more information please see the Fund's prospectus or by visiting www.polarcapital.co.uk.

Intended retail investor

This product is intended for all investors (including those with a basic level of investment knowledge) who are seeking a return on their investment and who can accept the risk of losing some or all of their original investment. The product should be considered a medium to long-term investment, defined as three years or more. This product is suitable for investors seeking an investment with sustainable characteristics.

Additional Information

The product's administrator is Northern Trust International Fund Administration Services (Ireland) Limited and the depositary is Northern Trust Fiduciary Services (Ireland) Limited, both of Georges Court, 54-62 Townsend Street, Dublin, Ireland D02 R156. Further information and corporate documentation including the latest and historic Annual and Interim Reports, can be obtained in English from the website: www.polarcapital.co.uk. Please speak to your financial adviser for further information.

Share prices will be published on www.polarcapital.co.uk on each valuation day. Please refer to the Company's prospectus for information on buying, switching and selling shares in the Fund. Shares can be bought and sold on any dealing day, where banks are normally open for business in the United Kingdom and Ireland, before 15:00 (Irish time) on that relevant day. Further information can be found under "How long should I hold it and can I take money out early?" The product manufacturer can cancel or redeem shares at the discretion of the Directors, by giving not less than 30 days' notice in writing to the relevant Shareholders. Please refer to Prospectus for more information.


What are the risks and what could I get in return?

Risk Indicator



Lower risk

Higher risk



The risk indicator assumes you keep the product for 5 years.

The actual risk can vary significantly if you cash in at an early stage and you may get back less.

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this product as 5 out of 7, which is a medium-high risk class. This rates the potential losses from future performance at a medium-high level and poor market conditions will likely impact the value of your investment.

If the product currency differs from your investment currency, the following applies: **Be aware of currency risk. You will receive payments in a different currency, so the final return you will get depends on the exchange rate between the two currencies. This risk is not considered in the indicator shown above.**

Please refer to the Prospectus for full details about other risks

materially relevant to the product that are not included in the summary risk indicator.

This product does not include any protection from future market performance so you could lose some or all of your investment.

If we are not able to pay you what is owed, you could lose your entire investment.

Performance Scenarios

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the product and a suitable benchmark over the last 10 years. The scenarios shown are only an indication of some of the possible outcomes based on recent returns. Actual returns could be lower. In particular, the figures quoted for the favourable performance, while based on actual performance, relate to performance during a period of exceptional circumstances that are not likely to be repeated. Markets could develop very differently in the future and past performance is not a guarantee or a reliable guide to future performance. The value of your investment may go down as well as up, and may vary.

The stress scenario shows what you might get back in extreme market circumstances.

Recommended Holding Period: 5 years			
Investment: EUR 10,000			
Scenarios		If you exit after 1 year	If you exit after 5 years (recommended holding period)
Minimum: There is no minimum guaranteed return if you exit before 5 years. You could lose some or all of your investment.			
Stress	What you might get back after costs	3,250 EUR	2,330 EUR
	Average return each year	-67.48%	-25.28%
Unfavourable	What you might get back after costs	7,700 EUR	9,080 EUR
	Average return each year	-23.01%	-1.91%
Moderate	What you might get back after costs	11,410 EUR	19,210 EUR
	Average return each year	14.12%	13.95%
Favourable	What you might get back after costs	15,270 EUR	25,890 EUR
	Average return each year	52.72%	20.95%

The unfavourable scenario occurred for an investment between March 2024 and April 2025.

The moderate scenario occurred for an investment between February 2020 and February 2025.

The favourable scenario occurred for an investment between August 2016 and August 2021.

What happens if FundRock Management Company (Ireland) Limited is unable to pay out?

For the protection of investors the Fund's assets are held by an independent depositary, so the Fund's ability to pay out would not be affected by the insolvency of FundRock Management Company (Ireland) Limited. If the Fund is terminated or wound up, the assets will be liquidated, and you will receive an appropriate share of any proceeds but you may lose part or all of your investment. There is no compensation scheme protecting you from this scenario.

What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

Costs over time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product does. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed in the first year, you would get back the amount that you invested (0 % annual return). For the other holding periods we have assumed the product performs as shown in the moderate scenario.

Investment: EUR 10,000	If you exit after 1 year	If you exit after 5 years
Total costs	216 EUR	1,871 EUR
Annual cost impact (*)	2.2%	2.3%

(*) This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 16.3% before costs and 14.0% after costs.

Figures may not sum due to rounding.

Composition of costs

One-off costs upon entry or exit		If you exit after 1 year
Entry costs	0.00% There is no entry fee for this product. However the product may charge an entry fee of up to 5% in the future.	0 EUR
Exit costs	0.00% There is no exit fee for this product.	0 EUR
Ongoing costs taken each year		If you exit after 1 year
Management fees and other administrative or operating costs	1.11% of the value of your investment per year.	111 EUR
Transaction costs	0.15% of the value of your investment per year. This is an estimate of costs incurred when we buy and sell underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	15 EUR
Incidental costs taken under specific conditions		If you exit after 1 year
Performance fees	10.00% a year of any returns the Fund achieves above the benchmark for these fees.	90 EUR

How long should I hold it and can I take my money out early?

Recommended holding period: 5 years

Investment in this Fund may be appropriate for investors who plan to invest over the medium to long term (3 to 5 years). The recommended holding period is shown for illustrative purposes only. There are no penalties if you wish to redeem your investment prior to the recommended holding period. The Shares can be sold by ordinary investors using an intermediary (e.g. a stockbroker) when the markets on which they trade are open. Redemption requests must be received by 15:00 (Irish time). Any requests received after this time will be treated as having been received the following dealing day. Please contact your broker, financial advisor or distributor for information on any costs and charges relating to the sale of shares. An intermediary is likely to apply a commission to purchases and sales. The above mentioned period has been defined in accordance to the product characteristics. Please refer to the Prospectus for further information regarding redemption or switching requests.

How can I complain?

If you have a complaint about the product, this document or the conduct of the manufacturer, please contact FundRock Management Company (Ireland) Limited ire-complianceteam@fundrock.com. Alternatively, you can also contact Polar Capital's investor relations team via email: Investor-Relations@polarcapital.co.uk or call +44 (0) 207 227 2700. Additionally, can also write to Polar Capital, 16 Palace Street, London SW1E 5JD, United Kingdom.

Other relevant information

The current performance scenarios and past performance of the Fund can be found by visiting www.polarcapital.co.uk

The representative in Switzerland is FundRock Switzerland SA, Route de Cité-Ouest 2, 1196 Gland, Switzerland. The paying agent in Switzerland is Banque Cantonale de Genève, 17 quai de l'Île, 1204 Geneva, Switzerland. The Prospectus, the Key Information Documents (KIDs), the Articles of Association and the annual and semi-annual reports can be obtained free of charge from the representative agent in Switzerland.